Sean Saint

Why the 3ml Glass Syringe is the New Standard in California ☀️⚖️ While the 1ml has long been the industry baseline, the California market is seeing a massive shift driven by local regulations. Our data confirms this: In the last 6 months, we’ve shipped over 1.2 Million units of our 3ml borosilicate glass syringes specifically to California. 📈 Why the surge in 3ml? As California’s compliance and packaging standards evolve, more brands are moving toward larger, multi-use glass formats for: Regulatory Alignment: Adapting to specific dosing and labeling requirements unique to the Golden State. Premium Preservation: Our medical-grade borosilicate glass ensures that larger oil volumes maintain their terpene profile and purity without leaching. Market Differentiation: With 1ml being the standard everyone knows, the 3ml offers a "Value & Professional" image that stands out on the shelf. Is your brand prepared for the regulatory shift? While other states haven't followed suit yet, California is—as always—the trendsetter. With 1.2M units already delivered, our supply chain is optimized for the California "April Rush." Don't let logistics spikes or inventory shortages catch you off guard. #CaliforniaCannabis #CannabisCompliance #3mlSyringe #GlassSyringes #PackagingRegulations #VapeIndustry #SupplyChain

1

𝐅𝐫𝐨𝐦 𝐅𝐫𝐢𝐞𝐧𝐝 𝐭𝐨 𝐌𝐞𝐧𝐭𝐨𝐫: 𝟓 𝐔𝐧𝐟𝐨𝐫𝐠𝐞𝐭𝐭𝐚𝐛𝐥𝐞 𝐋𝐞𝐬𝐬𝐨𝐧𝐬 𝐟𝐫𝐨𝐦 𝐑𝐚𝐲 𝐂𝐨𝐡𝐞𝐧 I’ve been lucky to call Ray Cohen both a mentor and a friend. Recently I drove up the SoCal coast to spend an afternoon with him. We talked about fishing, life, and our families. And of course we couldn't help but chat medtech. He doesn’t just build companies — he builds teams that win, stories that raise capital, and cultures that last. Here are 5 lessons that stuck with me from our conversations — and they’re worth passing on: 🧠 𝟏. 𝐁𝐞𝐭 𝐁𝐢𝐠 𝐨𝐧 𝐚 𝐁𝐢𝐠 𝐒𝐭𝐨𝐫𝐲 Don’t waste your time on incremental tech. Find a massive TAM and build a story around a radically better solution. 🚀 𝟐. 𝐈𝐧𝐯𝐞𝐬𝐭 𝐢𝐧 𝐂𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐄𝐚𝐫𝐥𝐲 Axonics hired 100 reps a year before FDA approval — and trained them for 9 months. Sales exploded from day one. That’s what urgency + conviction looks like. 💸 𝟑. 𝐃𝐨𝐧’𝐭 𝐅𝐞𝐚𝐫 𝐃𝐢𝐥𝐮𝐭𝐢𝐨𝐧 — 𝐅𝐞𝐚𝐫 𝐈𝐫𝐫𝐞𝐥𝐞𝐯𝐚𝐧𝐜𝐞 “100% of nothing is nothing.” Raise what you need, when you need it. Execution builds value faster than ownership alone. 🧑‍🤝‍🧑 𝟒. 𝐇𝐢𝐫𝐞 𝐭𝐡𝐞 𝐑𝐢𝐠𝐡𝐭 𝐏𝐞𝐨𝐩𝐥𝐞, 𝐓𝐡𝐞𝐧 𝐏𝐚𝐲 𝐓𝐡𝐞𝐦 𝐭𝐨 𝐖𝐢𝐧 Ray personally interviewed 500+ team members. He paid top reps nearly $1M/year and gave them equity. That’s how you build loyalty and accountability. 📣 𝟓. 𝐒𝐩𝐞𝐚𝐤 𝐏𝐥𝐚𝐢𝐧𝐥𝐲. 𝐋𝐞𝐚𝐝 𝐀𝐮𝐭𝐡𝐞𝐧𝐭𝐢𝐜𝐚𝐥𝐥𝐲. No jargon. No posturing. Just real talk, clear expectations, and full transparency. It builds trust fast — especially when things get hard. Ray once told me: “You have to forecast the future — then go make it come true.” That’s what leadership looks like in MedTech. #medtech #medicaldevices #medicaldevice #medicaldevicesales #medicalsales #digitalhealth

155

10 Comments

🔹 $𝟑.𝟕𝐁 𝐄𝐱𝐢𝐭. 𝐎𝐧𝐞 𝐋𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩 𝐏𝐡𝐢𝐥𝐨𝐬𝐨𝐩𝐡𝐲. I asked Ray Cohen, the CEO behind Axonics' $3.7 BILLION exit, how he earned real loyalty from his team. 👇️ He didn’t talk about perks. Or ping pong tables. Or feel-good slogans. Instead, he said something radical in its simplicity: 👉 “Treat them with respect. Pay them well. And give them a piece of the pie.” In other words: 🧠 Transparency over secrets. 🤝 Ownership over employment. 💬 Real talk over corporate jargon. When a founder like Ray opens the books, shares the vision, and gives real equity—people don’t just work for a salary. They build like it’s their company. Let this sink in: If your door is closed, your team is opening Slack, whispering: “What’s going on in that room?” Because culture is created in the absence of clarity. 📌 Leadership = openness. 📌 Loyalty = ownership. 📌 Culture = your real compensation package. If you're scaling a MedTech company (or any startup), Ray's advice isn’t just good HR—it’s good business. Lead like every team member could be your cofounder. That’s how billion-dollar trust is built. 𝑰𝒇 𝒕𝒉𝒊𝒔 𝒓𝒆𝒔𝒐𝒏𝒂𝒕𝒆𝒔, 𝒓𝒆𝒑𝒐𝒔𝒕 𝒕𝒐 𝒔𝒉𝒂𝒓𝒆 𝒘𝒊𝒕𝒉 𝒐𝒕𝒉𝒆𝒓𝒔 ♻️ 𝒂𝒏𝒅 𝒇𝒐𝒍𝒍𝒐𝒘 Omar M. Khateeb 𝒇𝒐𝒓 𝒎𝒐𝒓𝒆 𝒊𝒏 𝒇𝒖𝒕𝒖𝒓𝒆 #medtech #medicaldevices #medicaldevice #medicaldevicesales #medicalsales #digitalhealth

73

8 Comments

Kestra Medical Technologies Reports First Quarter Fiscal 2026 Financial Results KIRKLAND, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the first quarter fiscal 2026, which ended July 31, 2025. Financial Highlights Generated revenue of $19.4 million in Q1 FY26, an increase of 52% compared to the prior year period. Expanded gross margin to 45.7% in Q1 FY26 compared to 32.9% in the prior year period. Increased FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25. “We had a strong start to fiscal 2026, with our sustained commercial momentum generating revenue growth of over 50% in the first quarter,” said Brian Webster, President and CEO. “We also continued to make progress on several key operational objectives, including growing the commercial organization, enhancing our revenue cycle management capabilities, and expanding gross margin. As we progress on our journey to category leadership, we remain focused on both market share capture and growing the wearable defibrillator market, while executing on our commitments to patients and their prescribers.” First Quarter Fiscal 2026 Financial Results Total revenue was $19.4 million, an increase of 52% compared to the prior year period. 4,205 prescriptions were written for the ASSURE® system, an increase of 51% compared to the prior year period. Revenue growth was driven by higher market share with existing customers and activation of new accounts. Revenue also benefited from a higher mix of in-network patients and improvements in revenue cycle management capabilities. Gross profit was $8.9 million compared to $4.2 million in the prior year period. Gross margin expanded to 45.7% compared to 32.9% in the prior year period, driven by volume leverage and a higher mix of in-network patients. GAAP operating expenses were $37.7 million and included $2.9 million of non-recurring new public company costs. GAAP operating expenses were $22.6 million in the prior year period. Excluding non-recurring new public company costs and share-based compensation expense, operating expenses were $30.3 million in Q1 FY26. The increase was attributable to growth in expenses related to commercial and revenue cycle resources. GAAP net loss and comprehensive loss was $25.8 million compared to GAAP net loss and comprehensive loss of $20.3 million in the prior year period. Adjusted EBITDA* loss was $19.4 million compared to an adjusted EBITDA loss of $15.7 million in the prior year period. Cash and cash equivalents totaled $201.2 million as of July 31, 2025. Fiscal Year 2026 Revenue Guidance Kestra is increasing its FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25. This compares to prior FY26 revenue guidance of $85 million.

121

6 Comments

Cell therapy development can’t rely on a blueprint.​ Every project comes with its own technology, constraints, and curveballs – so the Fast Trak services team designs solutions that are just as unique as the therapies they support.​ “Every cell type, facility, and workflow tell a different story. The right process has to be built around it.”​ Masashi Nasukawa, Fast Trak Solutions Specialist in Japan, has seen how different each team’s reality can be. “I want people to know they don’t have to figure it out alone.”​ That’s a theme you’ll hear across our global Fast Trak services network.​ “The organizations we support often treat us as an extension of their scientific team,” says Mojtaba Parvizi, Global Director of Fast Trak Solutions. “We brainstorm, run experiments, and analyze data side‑by‑side to move therapies toward clinical development and commercialization.”​ Process is one part. Training is the multiplier.​ “Cell therapy manufacturing doesn’t scale like ‘one bioreactor equals 100 plates,” notes Mingming Li, Global Clinical Partnerships Leader. “We help teams scale from small dishes to commercial systems – and we train them to actually run those GMP processes, troubleshoot independently, and understand the regulatory landscape they’re stepping into.”​ The problem‑solving drive is universal across the team. ​ “When someone brings us a new question, my instinct is always: let’s test it,” says Sabrina Carmichael, Global Technical Leader. “We talk openly about what works, what doesn’t, and what the data says.”​ And if a solution doesn’t exist yet, we build one.​ Yi Jin, Fast Trak Solutions Leader for Cell Therapies in China, shared a recent example:​ “A team needed to integrate microbeads instead of the more common nanobeads into a scalable TCR‑T workflow. We designed a custom approach that met their needs and simplified their process.”​ If you’re working through challenges in process development, scale‑up, or regulatory readiness, this team is ready to share what they’ve learned.​ Join us for a live Q&A on tackling cell therapy development challenges.​ Reserve your spot: https://okt.to/E38xco

100

1 Comment

🚀 A new customizable autoinjector option on the market! I just read a great article on Plastics Today about the new A.i.r. autoinjector platform from MGS Mfg. Group, a flexible, highly customizable delivery solution designed to accelerate development and broaden therapeutic applications. What’s exciting about this platform: • Customizable fill volumes (0.3–2.25 mL) and activation profiles • Engineered simplicity with only seven plastic parts and two springs to reduce failure risk and streamline assembly • Designed to improve patient experience with features like audible feedback and adaptable ergonomics • Flexibility to support a wide range of drug viscosities and brand identities • Scales efficiently for both low- and high-volume programs — helping reduce development cost and speed time to market This kind of platform innovation is exactly what the industry needs as we see more combination products and personalized therapies. 👉 Read more here: https://lnkd.in/gzS-YAp2 #MedTech #DrugDelivery #Autoinjectors #CombinationProducts #Innovation

18

The Ramp is to BoneFoam what the Tundra Cooler is to Yeti—the iconic product that started it all. Sometimes the best innovations are the simplest ones. The Ramp solved a fundamental problem in orthopedic positioning so effectively that surgeons consistently ask: "Why didn't I think of that?!" What makes it work: -Simple and superior surgical access and leg stability -Clean imaging with sufficient offset from the contralateral leg -Eliminates inefficient stacks of linens and the sterilization, OR and laundering time wasted managing them And like Yeti's Tundra, imitation is the sincerest form of flattery. When competitors try to copy what you built first, you know you've created something special. The original. The standard. The Ramp. #MedicalDevices #OrthopedicSurgery #SurgicalInnovation #MedTech #OREfficiency #HealthcareInnovation #ProductDesign #SurgicalExcellence

11

1 Comment